References of "Jerusalem, Guy"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAccelerated partial breast irradiation: state of the art
COUCKE, Philippe ULg; JANSEN, Nicolas ULg; JANVARY, Zsolt Levente ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 3-7

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for ... [more ▼]

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for less exposure of healthy tissue to higher radiation doses. However, evidence <br />issued from randomized trials is limited. European and American experts call our attention <br />to the potential dangers of widespread implementation of these techniques without any <br />long-term data on outcome and ask for complete information of patients on the potential <br />hazards and risks if accelerated partial breast irradiation is used instead of whole breast <br />irradiation. [less ▲]

Detailed reference viewed: 53 (8 ULg)
Full Text
Peer Reviewed
See detailFinal results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity
Garcia, A; Awada, A; Chan, S et al

in Journal of Clinical Oncology (2011), 29(supplement 27),

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailTrabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire.
GENNIGENS, Christine ULg; Jerusalem, Guy ULg

in Revue Médicale de Liège (2011), 66(7-8), 452-5

Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has ... [more ▼]

Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has proven its efficacy after failure of standard treatments: the trabectedin; its activity is based on interference with ADN repair mechanisms. Trabectedin has just been also validated and reimbursed in patients with ovarian cancer, in partially sensitive recurrence. In this paper, we will review the mechanism of action and the clinical results of trabectedin. [less ▲]

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailA propos d'un cas de rechute tardive de cancer du sein après traitement adjuvant
LOUSBERG, Laurence; SOMJA, Joan ULg; COLLIGNON, Joëlle ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 306-310

Detailed reference viewed: 78 (6 ULg)
Full Text
Peer Reviewed
See detailEditorial. Le cancer du sein.
JERUSALEM, Guy ULg; SCHEEN, André ULg

in Revue Médicale de Liège (2011), 66(5-6), 225-228

Detailed reference viewed: 22 (8 ULg)
Full Text
Peer Reviewed
See detail18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers
Withofs, Nadia ULg; Grayet, Benjamin ULg; Tancredi, Tino ULg et al

in Nuclear Medicine Communications (2011), 32(3), 168-176

Detailed reference viewed: 63 (25 ULg)
Full Text
Peer Reviewed
See detailCellules Tumorales Circulantes : détection, caractérisation et intérêts cliniques
Gilles, Christine ULg; COLLIGNON, Joëlle ULg; Noël, Agnès ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 279-84

The metastatic process generates circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) in bone marrow and other organs which can remain as occult metastases. Various methods and systems have ... [more ▼]

The metastatic process generates circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) in bone marrow and other organs which can remain as occult metastases. Various methods and systems have been developed to allow the isolation and identification of those cells but major technical limitations still exist. Research on CTCs is a nevertheless tremendously growing field of cancer research because of their potential clinical applications. CTCs indeed convey predictive information for the development of metastasis and recurrence, and prognostic information regarding patient survival. CTCs enumeration could also be used to monitor the effectiveness of adjuvant treatments. Moreover, enhancing our basic understanding of the metastatic process, CTCs, and DTCs in particular, are thought to contain subpopulations of cells with stem cells properties that would be responsible for relapses. [less ▲]

Detailed reference viewed: 114 (12 ULg)
Full Text
Peer Reviewed
See detailApport de la consultation oncologique multidisciplinaire dans le choix des options thérapeutiques
JERUSALEM, Guy ULg; COUCKE, Philippe ULg

in Revue Médicale de Liège (2011), 66(5-6), 311-314

Le diagnostic et la prise en charge thérapeutique du cancer deviennent extrêmement complexes. La concertation oncologique multidisciplinaire (COM) permet d’optimiser la prise en charge du patient atteint ... [more ▼]

Le diagnostic et la prise en charge thérapeutique du cancer deviennent extrêmement complexes. La concertation oncologique multidisciplinaire (COM) permet d’optimiser la prise en charge du patient atteint de cancer. La COM permet de confronter les différents points de vue de chaque intervenant afin que le plan thérapeutique soit réellement l’approche la plus prometteuse et rationnelle pour traiter le cancer et, dans un contexte de maladie incurable, pour favoriser au mieux la qualité de vie. Cependant, le patient a toujours le dernier mot. Il peut évidemment refuser pour des raisons personnelles le traitement optimal. [less ▲]

Detailed reference viewed: 75 (17 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein de la femme âgée
MARTIN, Marie; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 400-408

Detailed reference viewed: 36 (1 ULg)
Full Text
Peer Reviewed
See detailCancer du sein et métastases cérébrales
RORIVE, Andrée ULg; COLLIGNON, Joëlle ULg; MARTIN, Marie et al

in Revue Médicale de Liège (2011), 66(5-6), 299-305

Detailed reference viewed: 78 (1 ULg)
Full Text
Peer Reviewed
See detailLe cancer du sein chez la femme jeune
ANDRE, Chantal ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 397-399

Detailed reference viewed: 84 (11 ULg)
Full Text
Peer Reviewed
See detailAspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques
COLLIGNON, Joëlle ULg; Struman, Ingrid ULg; Tabruyn, Sébastien ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 393-396

Detailed reference viewed: 159 (28 ULg)
Full Text
Peer Reviewed
See detailTraitements ciblés dans le cancer du sein
JERUSALEM, Guy ULg; COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 379-384

Detailed reference viewed: 51 (8 ULg)
Full Text
Peer Reviewed
See detailPrise en charge et suivi d'une série consécutive de 411 patientes opérées pour cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 329-335

Detailed reference viewed: 44 (5 ULg)
Full Text
Peer Reviewed
See detailChimiothérapie et cancer du sein
COLLIGNON, Joëlle ULg; RORIVE, Andrée ULg; MARTIN, M. et al

in Revue Médicale de Liège (2011), 66(5-6), 372-378

Detailed reference viewed: 64 (11 ULg)
Full Text
Peer Reviewed
See detailHormonothérapie du cancer du sein
LIFRANGE, Eric ULg; ANDRE, Chantal ULg; BLERET, Valerie ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 367-371

Detailed reference viewed: 91 (18 ULg)